Condition: Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: Alentis Therapeutics AG
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 in combination with pembrolizumab in patients with Head and Neck Cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| University of Southern California USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| Yale University Yale Cancer Center | New Haven, Connecticut, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Washington University School of Medicine | Lake Saint Louis, Missouri, United States | — |
| Gabrail Cancer Center Research | Canton, Ohio, United States | — |
| University Health Network, Princess Margaret Cancer Centre | Toronto, Ontario, Canada | — |
| Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre | Bordeaux, France | — |
| Oncopole Claudius Regaud, Iuct-Oncopole | Toulouse, France | — |
| Institut Gustave Roussy | Villejuif, France | — |
| Prince Of Wales Hospital | Hong Kong, Hong Kong | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06054477